Treatment of additional SLAMF6+ AML cell lines with the antibody generated consistent induction of T cell-mediated killing and reduced the number of HNT-34 cells by 75%, KG-1 cells by 58% and THP-1 cells by 45% (Fig. 6c–e), with different degrees of T cell activation (Extended Data Fig. 7a). Here, SLAMF6 is linked to acute myeloid leukemia.